Bibliographic Details
| Title: |
Neutral sphingomyelinase regulates mechanotransduction in human engineered cardiac tissues and mouse hearts. |
| Authors: |
Turner, Daniel G. P., De Lange, Willem J., Zhu, Yanlong, Coe, Christopher L., Simcox, Judith, Ge, Ying, Kamp, Timothy J., Ralphe, J. Carter, Glukhov, Alexey V. |
| Source: |
Journal of Physiology; Sep2024, Vol. 602 Issue 18, p4387-4407, 21p |
| Subject Terms: |
SPHINGOMYELINASE, HYPERTENSION, PLURIPOTENT stem cells, CAVEOLAE, CERAMIDES |
| Abstract: |
Cardiovascular disease is the leading cause of death in the USA and is known to be exacerbated by elevated mechanical stress from hypertension. Caveolae are plasma membrane structures that buffer mechanical stress but have been found to be reduced in pathological conditions associated with chronically stretched myocardium. To explore the physiological implications of the loss of caveolae, we used human engineered cardiac tissue (ECT) constructs, composed of human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes and hiPSC‐derived cardiac fibroblasts, to develop a long‐term cyclic stretch protocol that recapitulates the effects of hypertension on caveolae expression, membrane tension, and the β‐adrenergic response. Leveraging this new stretch protocol, we identified neutral sphingomyelinases (nSMase) as mechanoregulated mediators of caveolae loss, ceramide production and the blunted β‐adrenergic response in this human cardiac model. Specifically, in our ECT model, nSMase inhibition via GW4869 prevented stretch‐induced loss of caveolae‐like structures, mitigated nSMase‐dependent ceramide production, and maintained the ECT contractile kinetic response to isoprenaline. These findings are correlated with a blood lipidomic analysis in middle‐aged and older adults, which revealed an increase of the circulating levels of ceramides in adults with hypertension. Furthermore, we found that conduction slowing from increased pressure loading in mouse left ventricle was abolished in the context of nSMase inhibition. Collectively, these findings identify nSMase as a potent drug target for mitigating stretch‐induced effects on cardiac function. Key points: We have developed a new stretch protocol for human engineered cardiac tissue that recapitulates changes in plasma membrane morphology observed in animal models of pressure/volume overload.Stretch of engineered cardiac tissue induces activation of neutral sphingomyelinase (nSMase), generation of ceramide, and disassembly of caveolae.Activation of nSMase blunts cardiac β‐adrenergic contractile kinetics and mediates stretch‐induced slowing of conduction and upstroke velocity.Circulating ceramides are increased in adults with hypertension, highlighting the clinical relevance of stretch‐induced nSMase activity. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Physiology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
